Urinary Stone Removal — Procedure Guide, Recovery & Risks | MyMedicPlus

Urinary stone removal encompasses a range of minimally invasive and surgical procedures to eliminate calculi (stones) from the kidneys, ureters, or bladder that are causing symptoms, obstruction, infection, or progressive renal damage. Urinary tract stones — composed of calcium oxalate (most common, 75-80%), calcium phosphate, struvite (infection-related), uric acid, or cystine — develop when the urine becomes supersaturated with stone-forming salts due to dehydration, dietary excess, metabolic disorders, or recurrent urinary tract infections. The three primary active removal modalities are: extracorporeal shock wave lithotripsy (ESWL), which uses focused acoustic shock waves to fragment stones from outside the body without any skin incision; ureteroscopy with laser lithotripsy (URS-LL), which passes a thin endoscope through the urethra and bladder to reach and fragment stones with a holmium or thulium laser; and percutaneous nephrolithotomy (PCNL), in which a nephroscope is introduced directly into the kidney through a 1 cm flank skin incision to remove large stones by direct fragmentation and extraction. A fourth option — retrograde intrarenal surgery (RIRS) using a flexible ureteroscope — is functionally equivalent to URS but specifically applied to intrarenal stones accessed from below. The optimal procedure for each patient is determined by stone size, location, composition (where known), density on CT (Hounsfield units), and patient anatomy.

Active stone removal is indicated for urinary tract stones that are too large to pass spontaneously, causing persistent obstruction or significant symptoms. Specific triggers for intervention include stones greater than 5–6 mm in the ureter (which have less than 50% chance of spontaneous passage); persistent severe renal colic unresponsive to analgesics for more than 4 weeks; urinary tract infection or fever complicating stone obstruction (a urological emergency requiring urgent drainage); obstruction causing progressive renal impairment or hydronephrosis; solitary functioning kidney; and bilateral ureteral obstruction. Stones smaller than 5 mm have a 70–80% spontaneous passage rate with hydration and alpha-blocker medication (tamsulosin) which relaxes the ureter to facilitate passage — these patients are managed conservatively with medical expulsive therapy in the first instance. Treatment modality is determined by stone characteristics (size, location, density, shape) and patient factors (anatomy, anticoagulation, obesity, pacemaker).

ESWL is performed on an outpatient basis without anaesthesia. The patient lies on a lithotripsy table and the stone is localised with X-ray fluoroscopy or ultrasound. A focused acoustic shock wave generator delivers 2,000–3,500 shock wave pulses over 30–60 minutes, directed precisely at the stone. The high-pressure pulses fracture the stone into fine fragments through a process of stress waves and cavitation. Fragmentation is confirmed on imaging and the patient discharged the same day to pass the fragments over 2–4 weeks. Ureteroscopy (URS) is performed under spinal or general anaesthesia. A thin flexible or rigid ureteroscope is advanced through the urethra and bladder into the ureter or kidney under fluoroscopic guidance. A Holmium:YAG laser fibre is passed through the scope and stone fragments are produced using either a dusting technique (converting stone to fine powder) or a fragmentation and basket technique (producing larger pieces that are retrieved with a nitinol basket). A JJ ureteral stent is inserted at the end of the procedure to maintain drainage and is removed cystoscopically at 1–2 weeks in clinic. PCNL requires CT planning, percutaneous access to the renal collecting system through the flank, balloon dilation of the track to 24–30 French, and stone clearance using a rigid nephroscope with ultrasonic or laser lithotripsy — an overnight hospital stay of 2–3 days is required.

The choice of intervention is guided by which modality offers the highest stone-free rate for the specific stone characteristics. Ureteroscopy with laser lithotripsy achieves stone-free rates of 90–95% for ureteral stones and 75–90% for renal pelvis stones in a single procedure — the highest single-session success rates among non-invasive approaches. ESWL achieves stone-free rates of 60–80% for stones under 1 cm in the upper ureter or kidney (the optimal ESWL target), declining significantly for larger stones (under 50% for stones over 2 cm) and very hard stones such as calcium oxalate monohydrate or cystine. PCNL achieves 85–95% stone-free rates for large (greater than 2 cm) or complex renal stones — the highest efficacy for the most challenging cases. Successful stone removal eliminates the acute obstruction and its consequences — renal colic, infection risk, and renal damage — and restores normal urinary tract anatomy and kidney function.

ESWL risks include failure to fragment (25–30% for hard stones or stones larger than 2 cm), ureteral obstruction from stone fragment accumulation in the ureter (steinstrasse, occurring in 3–5%), transient haematuria, and post-treatment renal pain from passing fragments. Repeated ESWL sessions may be required. URS risks include ureteral perforation (less than 1%), mucosal injury, post-operative urinary tract infection or urosepsis (3–5%), failed endoscopic access requiring stent placement and deferred procedure, and stent-related discomfort during the 1–2 week stent period. Residual stone fragments requiring re-treatment occur in 15–25% depending on stone burden. PCNL carries higher risks including blood transfusion requirement (1–3%), pleural injury (less than 1% for upper pole access), haemorrhage requiring angiographic embolisation (1–2%), and longer recovery. Stone recurrence rates are 30–50% over 5–10 years without metabolic evaluation and preventive measures.

ESWL patients are discharged the same day with mild flank discomfort and haematuria for 24–48 hours as fragments pass. Increased fluid intake of at least 2.5–3 litres daily facilitates fragment passage over 2–4 weeks and reduces the risk of new stone formation. A KUB X-ray or low-dose CT at 4–6 weeks confirms stone-free status. After URS, a ureteral stent causes bladder discomfort, urinary frequency, urgency, and loin pain with voiding until it is removed cystoscopically under local anaesthesia in clinic at 1–2 weeks. Alpha-blocker medication (tamsulosin) reduces stent discomfort. Most patients return to sedentary work within 2–3 days after URS. Urine should be strained to collect stone fragments for composition analysis — fragment composition guides dietary and pharmacological prevention. Stone composition analysis and metabolic stone evaluation (24-hour urine collection, serum calcium, uric acid, parathyroid hormone) is offered after first presentation or recurrent stones to identify treatable metabolic causes and guide preventive management.